GlobeNewswire·Mar 9, 2026, 5:30 AM ET

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

HCM

HUTCHMED Limited has initiated a market withdrawal and product recall of TAZVERIK® (tazemetostat) in the Chinese mainland, Hong Kong, and Macau following a voluntary withdrawal announcement by Ipsen in the US.
The withdrawal is driven by a recommendation from the Independent Data Monitoring Committee for the SYMPHONY-1 trial, which determined that risks from secondary hematologic malignancies outweigh potential benefits.
TAZVERIK® is being withdrawn for both follicular lymphoma and epithelioid sarcoma indications in China.
All active tazemetostat clinical trials and expanded access programs are being discontinued, and existing patients are advised to consult physicians immediately for alternative treatment options.
The ongoing SYMPHONY-1 trial will stop tazemetostat treatment for enrolled participants, switching them to standard of care (lenalidomide plus rituximab only), though the study will remain open for long-term safety follow-up without further enrollment.
HUTCHMED has suspended all sales and shipments, instructed healthcare institutions to cease prescribing the drug, and notified the China NMPA, Hong Kong Department of Health, and Macau Health Bureau.
HUTCHMED stated that the withdrawal is not expected to impact the Company's financial guidance, noting 2025 sales of TAZVERIK® were US$2.5 million.
TAZVERIK® received conditional approval from the NMPA for follicular lymphoma treatment, with continued registration subject to reporting changes in foreign regulatory status and new safety signals.